Serentis is a privately owned biopharmaceutical company whose objective is to innovate, acquire, develop and commercialise proprietary medicinal products.
Founded in 2006, the company is establishing a development pipeline of commercially attractive products. Our initial focus is in the areas of dermatology, wound-care and topically applied products.
Products are identified by our in-house, low-risk discovery function and through in-licensing and acquisition of near-clinical stage assets.
The management team of the company are industry veterans with a track record of delivering fast, efficient development programmes.
Our intention is to establish a clinical stage development pipeline and to move rapidly to clinical proof-of-principle testing with our lead compounds.
Serentis operates a virtual model and has an established network of Research and Development partner companies.
